PL3334760T3 - Kapowane i niekapowane cysteiny przeciwciał i ich zastosowanie w koniugacji przeciwciał z lekami - Google Patents

Kapowane i niekapowane cysteiny przeciwciał i ich zastosowanie w koniugacji przeciwciał z lekami

Info

Publication number: PL3334760T3
Authority: PL; Poland
Prior art keywords: antibody; capped; uncapped; cysteines; drug conjugation
Prior art date: 2015-08-12

Application number

PL16760548T

Other languages

English (en)

Inventor

Xiaotian Zhong

Amarnauth Shastrie Prashad

Ronald William Kriz

Tao He

Will SOMERS

Wenge Wang

Leo Joseph LETENDRE

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-08-12

Filing date

2016-08-09

Publication date

2021-10-11

2016-08-09 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

2021-10-11 Publication of PL3334760T3 publication Critical patent/PL3334760T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Microbiology (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

PL16760548T 2015-08-12 2016-08-09 Kapowane i niekapowane cysteiny przeciwciał i ich zastosowanie w koniugacji przeciwciał z lekami PL3334760T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562204005P	2015-08-12	2015-08-12
EP16760548.4A EP3334760B1 (en)	2015-08-12	2016-08-09	Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation
PCT/IB2016/054789 WO2017025897A2 (en)	2015-08-12	2016-08-09	Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation

Publications (1)

Publication Number	Publication Date
PL3334760T3 true PL3334760T3 (pl)	2021-10-11

Family

ID=56855760

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL16760548T PL3334760T3 (pl)	2015-08-12	2016-08-09	Kapowane i niekapowane cysteiny przeciwciał i ich zastosowanie w koniugacji przeciwciał z lekami

Country Status (20)

Country	Link
US (2)	US10653794B2 (pl)
EP (2)	EP3334760B1 (pl)
JP (2)	JP6865209B2 (pl)
KR (2)	KR102146617B1 (pl)
CN (1)	CN107849121B (pl)
AU (1)	AU2016305331B2 (pl)
BR (1)	BR112018001904A2 (pl)
CA (1)	CA2938333A1 (pl)
DK (1)	DK3334760T3 (pl)
ES (1)	ES2864842T3 (pl)
HK (1)	HK1252799A1 (pl)
HR (1)	HRP20210579T1 (pl)
HU (1)	HUE053956T2 (pl)
IL (1)	IL257420B (pl)
MX (1)	MX2018001686A (pl)
PL (1)	PL3334760T3 (pl)
PT (1)	PT3334760T (pl)
RU (2)	RU2742260C2 (pl)
SI (1)	SI3334760T1 (pl)
WO (1)	WO2017025897A2 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2864842T3 (es) *	2015-08-12	2021-10-14	Pfizer	Cisteínas de anticuerpos protegidas y no protegidas, y su uso en la conjugación fármaco-anticuerpo
MX2019009372A (es) *	2017-02-08	2019-12-11	Pfizer	Produccion a gran escala para cisteinas de anticuerpo protegidas y no protegidas y su uso en la conjugacion de proteinas terapeuticas.
LT3661562T (lt) *	2017-08-04	2024-10-25	Amgen Inc.	Cys-mab konjugavimo būdas
US12109273B2 (en)	2019-02-15	2024-10-08	Wuxi Xdc Singapore Private Limited	Process for preparing antibody-drug conjugates with improved homogeneity
TWI756633B (zh)	2019-02-15	2022-03-01	大陸商上海藥明生物技術有限公司	具有改善的同質性的抗體－藥物綴合物、其藥物組合物、用途和製備方法
KR20230124971A (ko) *	2020-12-22	2023-08-28	노파르티스 아게	세포 배양 중 분비된 재조합 발현 단백질에서 시스테인잔기의 산화 수준을 감소시키는 방법
WO2023067626A1 (en) *	2021-10-20	2023-04-27	Dr. Reddy's Laboratories Limited	A cell culture process to produce an antibody composition

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5241078A (en) *	1988-06-14	1993-08-31	Cetus Oncology	Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
EP0604580A1 (en) *	1991-09-19	1994-07-06	Genentech, Inc.	EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
JP2002534119A (ja) *	1999-01-14	2002-10-15	ボルダーバイオテクノロジー，インコーポレイテッド	自由システイン残基を有するタンパク質の生産方法
US20050123532A1 (en) *	2001-12-04	2005-06-09	Takaharu Kouno	Method of activating protein
US8633300B2 (en) *	2005-06-17	2014-01-21	Novo Nordisk Healthcare Ag	Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
RU2424246C2 (ru) *	2006-05-26	2011-07-20	Ипсен Фарма С.А.С.	Способы сайт-специфического пегилирования
KR20100061442A (ko) *	2007-07-09	2010-06-07	제넨테크, 인크.	폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
JP2011509675A (ja) *	2008-01-18	2011-03-31	メディミューン，エルエルシー	部位特異的コンジュゲーションのためのシステイン操作抗体
US8623598B2 (en) *	2008-03-19	2014-01-07	Intelligent Bio Systems, Inc.	Methods and compositions for inhibiting undesired cleaving of labels
AU2010268690B2 (en)	2009-07-03	2011-11-10	Avipep Pty Ltd	Immuno-conjugates and methods for producing them
US9005926B2 (en) *	2009-10-02	2015-04-14	Biogen Idec Ma Inc.	Methods of preventing and removing trisulfide bonds
EP2507381A4 (en) *	2009-12-04	2016-07-20	Hoffmann La Roche	PLURISPECIFIC ANTIBODIES, ANTIBODY ANALOGUES, COMPOSITIONS AND METHODS
CN103068406B (zh) *	2010-06-08	2017-06-30	基因泰克公司	半胱氨酸改造的抗体和偶联物
EP2527429A3 (en) *	2011-05-27	2013-10-30	AbbVie Biotherapeutics Inc.	DAC HYP compositions and methods
MX353608B (es) *	2012-02-24	2018-01-19	Alteogen Inc	Anticuerpo modificado en el que el tema que comprende residuos de cisteina esta ligado, conjugado de farmaco de anticuerpo modificado que comprende el anticuerpo modificado y metodo de produccion para el mismo.
WO2014052650A2 (en)	2012-09-26	2014-04-03	Massachusetts Institute Of Technology	Modification of peptides via snar reactions of thiols with fluorinated aromatics
MX2016005784A (es) *	2013-11-04	2016-08-19	Pfizer	Conjugados de anticuerpo anti-ligando efrina-a4-farmaco.
US20170002393A1 (en) *	2013-12-04	2017-01-05	Immunogen, Inc.	Compositions and methods for antibody production
MX371147B (es)	2014-01-27	2020-01-20	Pfizer	Agentes citotoxicos bifuncionales.
RU2682645C1 (ru)	2015-03-20	2019-03-20	Пфайзер Инк.	Бифункциональные цитотоксические агенты, содержащие CTI фармакофор
ES2864842T3 (es) *	2015-08-12	2021-10-14	Pfizer	Cisteínas de anticuerpos protegidas y no protegidas, y su uso en la conjugación fármaco-anticuerpo

2016
- 2016-08-09 ES ES16760548T patent/ES2864842T3/es active Active
- 2016-08-09 CN CN201680047377.XA patent/CN107849121B/zh active Active
- 2016-08-09 PL PL16760548T patent/PL3334760T3/pl unknown
- 2016-08-09 RU RU2018105128A patent/RU2742260C2/ru active
- 2016-08-09 CA CA2938333A patent/CA2938333A1/en active Pending
- 2016-08-09 AU AU2016305331A patent/AU2016305331B2/en active Active
- 2016-08-09 WO PCT/IB2016/054789 patent/WO2017025897A2/en active Application Filing
- 2016-08-09 JP JP2018506438A patent/JP6865209B2/ja active Active
- 2016-08-09 DK DK16760548.4T patent/DK3334760T3/da active
- 2016-08-09 US US15/748,268 patent/US10653794B2/en active Active
- 2016-08-09 SI SI201631163T patent/SI3334760T1/sl unknown
- 2016-08-09 BR BR112018001904A patent/BR112018001904A2/pt active Search and Examination
- 2016-08-09 EP EP16760548.4A patent/EP3334760B1/en active Active
- 2016-08-09 KR KR1020187006927A patent/KR102146617B1/ko active IP Right Grant
- 2016-08-09 HU HUE16760548A patent/HUE053956T2/hu unknown
- 2016-08-09 EP EP20207006.6A patent/EP3808768A1/en active Pending
- 2016-08-09 RU RU2021101009A patent/RU2021101009A/ru unknown
- 2016-08-09 IL IL257420A patent/IL257420B/en unknown
- 2016-08-09 MX MX2018001686A patent/MX2018001686A/es unknown
- 2016-08-09 PT PT167605484T patent/PT3334760T/pt unknown
- 2016-08-09 KR KR1020207023230A patent/KR102319622B1/ko active IP Right Grant
2018
- 2018-09-20 HK HK18112100.2A patent/HK1252799A1/zh unknown
2020
- 2020-03-03 US US16/807,375 patent/US11980669B2/en active Active
2021
- 2021-04-05 JP JP2021063975A patent/JP2021118694A/ja active Pending
- 2021-04-12 HR HRP20210579TT patent/HRP20210579T1/hr unknown

Also Published As

Publication number	Publication date
HUE053956T2 (hu)	2021-08-30
EP3334760A2 (en)	2018-06-20
JP2021118694A (ja)	2021-08-12
RU2018105128A (ru)	2019-09-12
US20190030183A1 (en)	2019-01-31
ES2864842T3 (es)	2021-10-14
HRP20210579T1 (hr)	2021-05-28
US10653794B2 (en)	2020-05-19
IL257420B (en)	2022-08-01
RU2018105128A3 (pl)	2020-07-27
JP6865209B2 (ja)	2021-04-28
AU2016305331B2 (en)	2019-05-16
WO2017025897A2 (en)	2017-02-16
KR20180038041A (ko)	2018-04-13
KR102146617B1 (ko)	2020-08-20
EP3808768A1 (en)	2021-04-21
HK1252799A1 (zh)	2019-06-06
RU2742260C2 (ru)	2021-02-04
IL257420A (en)	2018-06-28
SI3334760T1 (sl)	2021-07-30
KR102319622B1 (ko)	2021-11-02
BR112018001904A2 (pt)	2018-09-18
DK3334760T3 (da)	2021-04-19
RU2021101009A (ru)	2021-02-20
CN107849121B (zh)	2021-11-09
CN107849121A (zh)	2018-03-27
US20200230256A1 (en)	2020-07-23
PT3334760T (pt)	2021-04-23
EP3334760B1 (en)	2021-03-10
AU2016305331A1 (en)	2018-02-15
US11980669B2 (en)	2024-05-14
KR20200100850A (ko)	2020-08-26
MX2018001686A (es)	2019-01-31
CA2938333A1 (en)	2017-02-12
WO2017025897A3 (en)	2017-04-06
JP2018525990A (ja)	2018-09-13

Publication	Publication Date	Title
HK1252799A1 (zh)	2019-06-06	封端和未封端的抗體半胱氨酸，及其在抗體-藥物綴合中的用途
IL267323A (en)	2019-08-29	Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof
HK1243414A1 (zh)	2018-07-13	苯並呋喃類衍生物、其製備方法及其在醫藥上的應用
IL247248A0 (en)	2016-09-29	Anti-dll3 antibodies and drug conjugates for use in melanoma
IL248239A0 (en)	2016-11-30	Drug conjugates - antibody against - her3, preparations containing them and their uses
HK1254864A1 (zh)	2019-07-26	Hbed-二膦酸鹽/酯、其放射金屬軛合物和它們作為治療診斷劑的用途
GB2562059B (en)	2020-08-12	Improvements in and relating to barriers
ZA201908091B (en)	2021-08-25	Indole-formamide derivative, preparation method therefor and use thereof in medicine
IL249453A0 (en)	2017-02-28	Texapyrin conjugates and preparations - pt(iv) for use in overcoming resistance to platinum
LT3544637T (lt)	2021-03-25	Natyvių omv ir antigeno konjugatai bei jų naudojimo būdas
GB201614162D0 (en)	2016-10-05	Antibodies, uses thereof and conjugates thereof
IL266112A (en)	2019-06-30	Antibodies against edb and antibody-drug conjugates
EP3632906C0 (en)	2023-12-13	AZAARYL DERIVATIVE, PRODUCTION PROCESS THEREOF AND APPLICATION THEREOF FOR USE IN PHARMACY
ZA201706254B (en)	2018-12-19	Oil blends, processes for the preparation thereof and their use in formulas
GB201419108D0 (en)	2014-12-10	Materials and methods relating to linkers for use in antibody drug conjugates
RS56132B1 (sr)	2017-10-31	Grupa za lepljenje sa uređajem za podesivi pristup kod laminator-utiskivača, odnosni laminator-utiskivač i postupak za podešavanje pristupa
FI20165821L (fi)	2018-05-02	Menetelmä fysikaalisten suureitten mittaamiseksi ja menetelmässä hyödynnettävä mittausjärjestely
EP3385281A4 (en)	2019-08-21	ANTIBODY FOR CROSS-LINKING TO HUMAN SEMA3A AND MOUSE, AND USE THEREOF
IL237283A0 (en)	2015-07-30	Dldh and its derivatives, and preparations containing them for medical use
GB201308136D0 (en)	2013-06-12	Agrochemical composition, method for its preparation and the use thereof
METROPOLIS	2014	THE SOCIAL AND THE NATIONAL QUESTION IN THE EASTERN METROPOLIS
GB201712096D0 (en)	2017-09-13	Immunogenic conjugates and use thereof
GB201609866D0 (en)	2016-07-20	Antibodies, uses thereof and conjugates thereof
GB201712343D0 (en)	2017-09-13	Agrochemical composition, method for its preparation and the use thereof